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Summary 
Human  lymphocytes with  natural  killer  (NK)  activity,  including most  activated  3'/8 +  T 
lymphocytes, recognize and lyse tumor target  cells without requiring recognition of major 
histocompatibility complex antigen. However,  unlike 3'/8 + T  lymphocytes, NK cells do not 
express  CD3/T  cell receptor (TCR)  molecules, and the receptors involved in ceU-mediated 
cytotoxicity are unknown. To further delineate circulating NK cells, we developed monoclonal 
antibodies (mAbs) against the human NK leukemia YT2C2. We report the isolation of a mAb 
termed BY55, recognizing at the cell surface a novel 80-kD protein with restricted expression, 
In addition to the immunizing cell line, this mAb binds to circulating NK cells, 3'/8*  cells, 
and a minor subset  of ot/B + T lymphocytes. Expression of the BY55 mAb-reactive epitope/ 
molecule is regulated by activation, as short-term culture of peripheral blood lymphocytes (PBL) 
with phorbol ester induced its downmodulation. Furthermore, BY55 mAb reactivity was found 
neither with the NK nor with the TCR a/B + and 3"/8 + clones tested.  Biochemical studies 
as well as phenotypic analysis revealed that this structure is different from all previously identified 
molecules on the lymphocyte cell surface. Interestingly, we found that BY55 + cells exert most 
NK  activity  obtained with  fresh  circulating lymphocytes. We  report  that  within  fresh  E 
rosette-positive PBL only a subset of the CD16 +, CD56 +, and CD57 + cells coexpressed BY55 
molecule, indicating that BY55 mAb defines a unique subset mediating NK activity of circulating 
PBL. 
N 
'K cells are circulating lymphocytes found within the 
large granular lymphocyte population (1, 2) and con- 
stitute, with CTL (3), the major cytotoxic effector lymphoid 
elements of the immune system.  The characteristic  surface 
markers expressed by NK cells are CD56 (4-6),  CD57 (4, 
5), CD16 (7-10), CD11b (11), and CDllc (11, 12). Most cir- 
culating cells with NK activity express the CD2 molecule 
but are distinct from the T lineage,  as they do not express 
CD3 and do not rearrange any of the TCR genes (13, 14). 
In addition, NK cells mediate cytotoxicity without requiring 
recognition of MHC molecules on target cells. However, most 
activated TCR 3'/8 lymphocytes (15-18),  and under certain 
circumstances some TCR o~/B cloned lymphocytes (19), can 
also mediate MHC-unrestricted cytotoxicity. The NK cell 
receptor(s) participating in target recognition remain(s) largely 
unknown despite extensive  studies (20-22). 
In an attempt to define NK cell-specific surface structures, 
we characterized  a mAb obtained by repeated immunization 
with YT2C2, a human cell line with NK functional charac- 
teristics.  This cell line was selected for intermediate affinity 
binding of 12sI-IL-2 with the IL-2R p75 subunit (23). In the 
present study, we report the isolation ofa mAb, termed BY55, 
reacting at the cell surface with a novel 80-kD protein struc- 
ture. BY55 mAb reactivity is observed with 15-25% of cir- 
culating lymphocytes. Two-color immunofluorescence staining 
of fresh E rosette-positive (E +) PBL obtained from normal 
individuals revealed that a sizeable proportion of CD3-negative 
and TCR 3,/8 + lymphocytes are  stained by BY55  mAb, 
whereas, in contrast, a minor subset ofCD8 + c~/~/+ T lym- 
phocytes expressed BY55-reactive molecule. Moreover, acti- 
vated PBL and TCR o~/B or 3'/8 T cell clones failed to ex- 
press the BY55 mAb-reactive epitope/molecule. To address 
the question as to whether the BY55 + circulating lympho- 
cytes could be responsible for NK activity, negative (comple- 
ment-dependent depletion) and positive (sorted population) 
selections of the BY55 mAb-reactive population were per- 
formed. Results indicate that NK activity is mediated by 
BY55 + circulating lymphocytes. As we found that the BY55 
mAb defined the circulating NK cell population, partly dis- 
tinct from those defined by CD56, CD57, or CD16 mAb, 
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culating competent cytolytic effectors in NK cells. 
Materials and Methods 
Production Of BY55 mAh  This mAb of IgM isotype was ob- 
tained by immunizing BALB/c mice with the human NK cell line, 
YT2C2, generously provided by Dr. S. Chouaib (IGK, Villejuif, 
France). Cell fusions were performed as previously described (24, 
25). The initial screening by indirect immunofluorescence and flow 
cytometry  using a FACStar  |  (Becton Dickinson & Co., Mountain 
View, CA) retained all hybridoma culture  supernatants reacting 
with the immunizing cells, but not with the T cell done JF1 (19) 
and  an  EBV-transformed B cell line.  Ascites were  purified by 
precipitating IgM proteins in dialysis with distilled water followed 
by gel filtration chromatography. 
mAbs.  CD3-FITC,  CD4-FITC,  CD8-FITC,  CD19-FITC, 
CD57-FITC, CD16, and CD56 were purchased from Immunotech 
(Luminy, France). TCK ~1 was kindly provided by Dr. M. Brenner 
and the anti-TCK ce/B BMA031 was a gift from Dr. A. Musitelli 
(Behring, Rueil, France). ~'CS1 was purchased from T Cell Sciences 
(Cambridge, MA). The anti-V~2, BB3 mAb was kind gift of Dr. 
A. Moretta. The mAbs CD2 (CD2Xll and D66), CD3 (CD3X3), 
CD4 (0516), CD8 (L533), CD25 (BC96), and BB18 were produced 
and purified in our laboratory. 
Isolation of Cell Populations.  Human PBMC were prepared by 
Ficoll-Isopaque density gradient centrifugation. The unfractionated 
population was separated into E rosette-negative  (E-) and E ro- 
sette-positive  (E +) populations by rosetting  with 5% SRBC as 
previously described (24). BY55-  E + PBL were obtained by fur- 
ther treatment of E + cells with BY55 mAb plus rabbit comple- 
ment. For the isolation of BY55  + and BY55-  cell populations, 
fresh PBL were stained by indirect immunofluorescence  with BY55 
mAb and sorted into BY55  + and BY55-  fractions using a FAC- 
Star microfluorometer (Becton Dickinson & Co.). Sorted popula- 
tions were collected as described elsewhere (26), were washed twice, 
and tested as effector cells in cytotoxic assays. Trypan blue exclu- 
sion was performed on the unsorted population and sorted popula- 
tions,  and the viability was always >90%. 
Immunofluorescence  Assays.  Indirect immunofluorescence assays 
were performed using a FITC-conjugated anti-mouse Ig. Fluores- 
cence was read using a FACStar  |  microfluorometer (Becton Dick- 
inson & Co.). For two-color immunofluorescence  experiments, cells 
were simultaneously incubated for 30 rain with a FITC-conjugated 
mAb and biotin-conjugated BY55 mAb. The cells  were then washed 
before an appropriate amount of PE-conjugated streptavidin was 
added. Alternatively, an indirect assay was done with some uncou- 
pled IgG mAb using an FITC anti-mouse IgG. After final washes 
the ceils were resuspended in 0.3 ml of cold 1% formalin solution 
in PBS. Purified BY55 antibodies were biotin labeled using a stan- 
dard protocol (26). Fluorescence emissions of FITC and PE were 
distinguished  using  530  +  15 and 575  -+  12.5 bandpass filters, 
respectively. The overlap in FITC and PE fluorescence emissions 
was corrected by using  an electronic compensation network. 
PMA.induced  Modulation of  Cell Su~ce Expression.  PBMC were 
incubated with PMA (Sigma Chemical Co., St. Louis, MO) at 50 
ng/ml in culture medium containing 10% NHS, at 37~  for indi- 
cated times. After extensive washing, cells were stained for im- 
munofluorescence using biotinylated mAbs. 
Labeling and Iraraunoprecipitations  of  Cell Suite Proteins.  YT2C2 
cells  were  t2sI surface radiolabeled  using  the  lactoperoxidase 
method as previously described (25). Aliquots of predeared lysates 
were immunoprecipitated with either rabbit anti-mouse  IgM Ab 
coupled to protein A-Sepharose beads as negative control, or with 
the same immunoabsorbant complex previously  coupled with BY55 
mAb. Immunoprecipitations, SDS-PAGE  analysis, and autoradiog- 
raphy were performed as described (25). 
Cytotoxic Assays.  Cytotoxicity assays were performed according 
to a standard SlCr release method (19, 26). All experiments were 
performed  with fresh effector  cells. Target cells  were the NK-sensitive 
cell line, K562. Assays at various E/T ratios with 5  x  103 51Cr- 
labeled target cells/well were carried out in triplicate, using 96- 
well V-bottomed microtiter plates. The percentage of lysis was de- 
termined as previously described (19, 26). 
~sults 
BY55 mAb Identifies a  Unique CD2 + Lymphocyte Subset. 
BY55 is an IgM mAb. Extensive phenotypic analysis revealed 
that, in addition to the immunizing cell YT2C2 and its pa- 
rental cell line YT, BY55 mAb only stained a subset of 10-25% 
of E +  PBL  (20 individuals  tested).  Specifically,  no BY55 
mAb staining could be detected among PHA- or IL-2-activated 
E + PBL, granulocytes, monocytes, platelets,  red blood cells, 
and bone marrow cells. In addition, BY55 mAb did not bind 
to 16 different leukemic cell lines,  5 EBV-transformed B cell 
lines, and 20 rlL-2-dependent CD3 + or CD3-  cell clones 
tested (data not shown). Next, we determined whether this 
expression was restricted to any particular subset of periph- 
eral blood CD2 +  cells  by two-color immunofluorescence 
staining of E + PBL derived from normal individuals. The 
results obtained with one representative donor's PBL with 
23%  of BY55 + cells are shown in Fig.  1. Among BY55 § 
cells,  50% expressed TCR tx/3, 25% expressed TCR "r/~, 
while the remaining 25% were unreactive with anti-TCR 
or CD3 mAb.  In addition, a minor proportion (2-4%) of 
the BY55 + cells were CD4 + , while 50% coexpressed CD8 
molecules.  Further,  within  BY55 §  TCR  3,//~ §  cells,  an 
equal proportion reacted with BB3 or ~'CS1 mAb. Conversely, 
a majority of CD2+CD3 -  cells were labeled by BY55 mAb. 
Thus, while BY55 mAb delineated a subset of cells clearly 
different from all well-identified T cell subsets, it was impor- 
tant to determine whether it was expressed by CD2 + cells 
known to exhibit NK activity. 
Differential Distribution of the NK-associated Molecules CD16, 
CD56, or CD57 and BY55 Monoclonal-reactive  Molecule.  There- 
fore, we first compared BY55 expression with the NK-asso- 
ciated molecules CD16,  CD56,  and CD57.  Table  1 shows 
the median percentages obtained in three independent two- 
color fluorescence experiments. When E + PBL were stained 
simultaneously with BY55 and CD16 mAb, only one-half 
of the CD16 + cells and 40% of the BY55 § cells coexpressed 
both markers.  Moreover, whereas two-thirds of CD56 + cells 
coexpressed BY55 molecules, only one-third of the lympho- 
cytes coexpressed CD57 and BY55 molecules. Therefore, ex- 
pression of the BY55 surface antigen appears to define a cir- 
culating  lymphocyte  subset  clearly  different  from  that 
previously defined as NK cells by CD16, CD56,  or CD57 
mAbs. 
Downmodulation of  BY5  5 Molecule afier PMA Activation.  Be- 
cause BY55 mAb failed to stain any short- and long-term 
1122  Circulating  Natural Killer-specific  Cell Surface Marker CD19  CD3  CD4  CD8 
@ 
r  ￿9 
!i 
318o 
.:-;o  ~lll 
......  I  ........  I  ...... 
s  I 
"l  ........  I  ..... 
TCR81 
~  I'il 
! 
883 
........  I  -Y  .......  t  ..... 
8TCSl 
+ 
L~-  ':i  , ....  :.,~  ........  ,  ...... 
8MA031 
........  I  ...... 
Figure  1,  Two-color immunofluorescence  analysis of BY55 expression in E + PBL. Cells from a representative normal donor were labeled by direct 
or indirect immunofluorescence  with different mAbs in combination with biotin-coupled BY55 mAb and streptavidin-PE  as described in Materials 
and Methods.  Samples were then analyzed by flow cytometry.  Division in quadrants  was established on the basis of one-color immunofluorescence 
analysis of samples for each individual  experiment.  Numbers in the top right corner of two-dimensional  contour plots  indicate  the percent  of cells 
included  within each quadrant. 
activated lymphocytes irrespective of their phenotypes,  we 
investigated whether a potent inducer of lymphocyte stimu- 
lation such as PMA was capable of modifying BY55 expres- 
sion.  A  24-h  incubation  of E +  PBL (containing  28%  of 
BY55 + cells) with PMA at 50 ng/ml resulted in an almost 
complete disappearance of BY55 + cells as shown in Fig. 2. 
The decrease in BY55 § cells is time dependent  and is ob- 
served in the presence of PMA as early as 15 min. As control 
the staining of BB18 mAb was simultaneously analyzed and, 
as expected, the reexpression of BB18 molecule was observed 
at 24 h  (24).  It should be noted that reexpression of BY55 
Table  1.  Percentage of E + PBL  Coexpressing CD16,  CD56, 
or CD57 Molecule with BY55 *nAb-reactive Antigen 
Cell 
reactivity  CD16 ~  CD16-  CD56 +  CD56-  CD57 +  CD57- 
BY55 §  6  9  10  7  9  7 
BY55-  6  79  5  78  23  61 
Two-color immunofluorescence  analysis of resting E +  PBL  was  per- 
formed as described in Materials and Methods. Results are the mean per- 
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Figure  2.  Kinetic of percentage of BY55 + cells downmodulated  during 
PMA stimulation.  Cells were incubated  with 50 ng/ml of PMA or with 
medium alone (control cells) for various period of time and stained with 
BY55, BB18, and CD2 mAbs for indirect  immunofluorescence  analysis. 
Percentage of cells downmodulated were calculated at each time of incu- 
bation as follows: 1  -  (% mAb-reactive cells in PMA culture/% mAb- 
reactive cells in medium culture). 
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tion  analysis  of BY55  molecule. 
12SI-labded  lysates  from YT2C2 
cells  were  immunoprecipitated 
with  control  immunoabsorbant 
(lanes  I  and  3)  or  19/55  mAb 
(lanes 2 and 4). Samples were ana- 
lyzed by 10%  SDS-PAGE under 
nonreducing (NR) and reducing 
(R)  conditions. 
molecule was not  observed even after 3  d  of culture  (data 
not  shown). 
BY55 mAb Identifies a Novel 80-kD Molecule.  To confirm 
that BY55 mAb-reactive surface molecule was different from 
all previously defined T  and NK cell surface structures,  we 
performed the biochemical identification of the surface mol- 
ecule recognized by BY55 mAb.  YT2C2  cells  were exter- 
nally radiolabeled by the lactoperoxidase method and lysed. 
BY55 immunoprecipitates  obtained from these labeled cell 
lysates were next analyzed by SDS-PAGE. Autoradiography 
shown in Fig. 3 indicated, in the BY55 mAb immunoprecip- 
itate, a predominant broad band migrating with an approxi- 
mate molecular mass of 80 kD, under both nonreducing and 
reducing conditions. The immunoprecipitates obtained from 
a lysate of peripheral  blood population  presented  identical 
characteristics  (data  not  shown). 
NK Activity of Circulating  Lymphocytes  Is Restricted  to the 
BY55 + Subset.  As most CD2+CD3 -  cells were stained by 
BY55 mAb, it was important to determine the cytotoxic ac- 
tivity of these BY55 + cells. First,  we looked at whether NK 
activity of E + PBL was abolished after depletion in BY55 + 
cells by C-dependent lysis. Fig. 4 A  shows the representative 
results obtained with one normal donor. Similar results were 
obtained with five different individuals.  Fresh E + PBL were 
treated  or sham  treated with BY55 mAb and complement 
before tested as effector cells against the NK-sensitive target 
cell K562 at different E/T ratios.  Whereas no difference in 
terms of killer activity was observed in untreated and sham- 
treated E + PBL (data not shown), the BY55- E + PBL failed 
to exhibit any significant NK activity even at an E/T ratio 
of 100:1. Thus, BY55 § PBL were necessary for NK activity 
against standard target cells.  To determine whether BY55 § 
circulating lymphocytes represented the effector of NK ac- 
tivity, PBL were labeled with BY55 and sorted into BY55 § 
cells  and BY55-  cells  using  a FACS  |  The  results  from  a 
representative experiment  is presented in Fig.  4 B.  Whole 
PBL and BY55 mAb-labeled PBL of this donor exhibited 
a strong NK activity. Interestingly, and as expected from the 
later experiments,  BY55-  cell population  was deprived of 
NK activity. Moreover, BY55 + population was greatly en- 
riched in cells mediating NK activity, as shown by a higher 
percentage of specific SlCr release  at each E/T ratio.  It has 
to be noted that  treatment  of PBL by BY55 mAb did not 
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Figure  4.  (A)  Effect  of CD2+BY55 +  cell depletion  from  E +  PBL 
population  on NK activity. Elimination of CD2+BY55 + cells was per- 
formed with complement lysis as described in Materials and Methods. Non- 
treated  E +  PBL representing  the control population  (diamonds) and its 
counterpart,  E + BY55-  cells (circles), were used as effector cells against 
K562 target cells in a 4-h SlCr release assay. One representative experi- 
ment obtained with a normal donor, which displays 70% of BY55-positive 
cells among CD2+CD3 -  population,  is shown.  Results represent mean 
of triplicate experiments and are expressed as percent of specific cytotoxic 
activity.  (B) Determination of the NK activity mediated by sorted BY55 + 
and BY55-  PBL. Freshly isolated PBL were labeled with BY55 mAb for 
indirect immunofluorescence. These treated cells were either used directly 
as  effector cells (triangles), or  sorted  into  BY55 +  (squares) and  BYS5- 
(circles)  effector cells. Untreated PBL were also tested as effector cells (dia- 
monds) against  K562  target  cells. 
Discussion 
In the present report we described a novel 80-kD mole- 
cule exclusively expressed by a subset of circulating human 
CD2 + lymphocytes responsible for killer activity against the 
standard NK-sensitive target cells. We found that activation 
of E + PBL rapidly resulted in the disappearance of the mol- 
ecule/epitope detected by the BY55 mAb at the cell surface. 
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responds to a cell surface differentiation antigen delineating 
a functional  circulating  lymphocyte population. 
Analysis of BY55 distribution  on E + PBL demonstrated 
that  the BY55 + subset was mostly confined to the CD3- 
and  to  TCR 3,/8 + lymphocytes.  Further,  double fluores- 
cence analysis  showed that a subset of CD16 + , CD56 + , or 
CD57 +  cells  coexpressed  BY55-reactive  molecule.  These 
molecules are the prototypic antigens expressed by NK cells 
(27-29),  and as we found that  removal of BY55 + cells  in 
E §  PBL resulted  in  the abolition  of the NK activity,  the 
BY55 mAb appears to define the active subset of E + PBL 
with NK activity. This finding was further confirmed and 
extended to PBL, with the observation that positively selected 
BY55 +  circulating  lymphocytes exhibited  highly  ef~cient 
NK activity. Insignificant killer activity was found with the 
sorted BY55- population.  In contrast to CD16 (RFctklII), 
a molecule expressed on NK cells, neutrophils and activated 
macrophages (30), and to CD56 (isoform of NCAM) (31), 
the expression of the BY55 molecule is restricted to a sub- 
set of lymphoid cells containing  mainly circulating  CD2 + 
CD3-  and CD2 + 3,/8 + cells.  A  mAb termed anti-Kp43, 
recognizing a 43-kD disulfide-linked dimer, has been reported 
with a similar pattern of reactivity (32, 33). It was selected 
for its ability to inhibit IL-2-dependent proliferation. In con- 
trast to BY55, anti-Kp43 reacts with cultured NK cells and 
PHA-activated PBL, stimulates IL-2-induced proliferative re- 
sponseg and induces MHC-unrestricted cytotoxidty. Nakamura 
et al.  (34) reported two mAbs, YTA-1 and YTA-2,  raised 
against YT cells. These mAbs recognize a 75-kD protein selec- 
tively expressed by large granular lymphocytes and all periph- 
eral blood T  cells.  Interestingly,  it was found that the YT- 
1/2 mAb were mitogenic for freshly isolated PBMC and could 
induce CD25 expression.  As we were unable to find such 
agonistic properties of BY55, we exclude the possibility that 
the YT-1/2 mAb recognizes the BY55 molecule. Another 
mAb termed GL183 (35) identifies a subset of CD16 + NK 
cells.  However, it differs from BY55 in its tissue reactivity 
and in its functional properties. Moreover, apparent molec- 
ular masses of the structures recognized by BY55 and GL183 
are not identical. 
Finally,  it seems unlikely that BY55 reacts with Ib2tkp75 
as BY55 does not inhibit IL-2-induced proliferation and IL- 
2-induced cytotoxic activity of NK cells. Comparative pheno- 
typic analysis  with an anti-IL-2Rp75,  TU27 (36), revealed 
that  TU27,  but not  BY55,  stained IL-2-dependent  T  cell 
clones. 
The fact that the expression of BY55 appears to be restricted 
to NK and 3,/~ + circulating cells raised the possibility that 
these populations share phenotypic characteristics in addition 
to  their  non-MHC-restricted  killer  activity  (18).  Further 
studies are underway to determine whether the BY55 mole- 
cule is preferentially expressed by the CD8 + or the CDS- 
cells in the TCR 3,//J + and in the CD3-  lymphocyte sub- 
sets. As BY55 cell surface expression is associated with a high 
lytic  activity,  experiments  in  progress  should  determine 
whether the small subset of circulating CD3 +  CD8 +  BY55 + 
cells  exclusively mediates  CTL  activity. 
In conclusion, BY55 mAb, which stains  a minor CD2 § 
subset, constitutes a unique tool to identify all circulating 
NK lymphocytes.  Because the expression of this molecule 
is restricted to circulating  uncultured lymphocytes, it represents 
a new marker  of the differentiation/activation  state of the 
NK cell subset (3).  This probe will contribute to a better 
understanding  of the  immunobiology  of circulating  NK 
effector lymphocytes and to delineation  of their  participa- 
tion  in inflammatory  disorders. 
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